Canada markets close in 3 hours 12 minutes

I-Mab (0VY.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
1.1700+0.0600 (+5.41%)
As of 08:01AM CEST. Market open.
Full screen
Previous Close1.1100
Bid1.2200 x N/A
Ask1.2600 x N/A
Day's Range1.1700 - 1.1700
52 Week Range1.0900 - 6.7500
Avg. Volume0
Market Cap99.83M
Beta (5Y Monthly)0.99
PE Ratio (TTM)N/A
EPS (TTM)-3.0600
Earnings DateAug 17, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est45.37
  • Reuters

    UPDATE 1-AbbVie terminates deal with I-Mab to develop cancer drug

    China-based biotech company I-Mab said on Friday that AbbVie has terminated a 2020 deal to co-develop and market I-Mab's lead cancer drug candidate lemzoparlimab. AbbVie's decision to scrap the deal comes after it pulled the plug on an early-stage study in August last year that was testing lemzoparlimab in combination with two other drugs for treating two types of blood cancers, myelodysplastic syndrome and acute myelocytic leukemia. The deal termination will be effective Nov. 20 this year, and will not affect upfront and milestone payments of $200 million that the company has received from AbbVie, according to I-Mab.

  • Thomson Reuters StreetEvents

    Half Year 2023 I-Mab Earnings Call

    Half Year 2023 I-Mab Earnings Call

  • Simply Wall St.

    Retail investors account for 40% of I-Mab's (NASDAQ:IMAB) ownership, while institutions account for 17%

    Key Insights I-Mab's significant retail investors ownership suggests that the key decisions are influenced by...